Epiprobe (奕谱生物)
Shanghai, China
Epiprobe is a biotechnology company specializing in tumor molecular diagnosis and precision medicine. It utilizes genome-wide DNA methylation detection methods to screen for cancer tumor markers across various therapeutic areas including oncology, urology, and women's health. The company offers products for early cancer screening and diagnosis, supported by extensive clinical validation in over 40 top-tier hospitals. Their proprietary TAGMe technology aims to enable early detection, diagnosis, and treatment of cancer to improve patient survival rates. With significant funding and international certifications, Epiprobe focuses on eliminating cancer at its inception through advanced genomic analysis and accessible diagnostic tools for healthcare professionals.
Company Info
- Founded
- 2018
- Website
- www.epiprobe.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Epiprobe (奕谱生物)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.